ResApp

By Jonah Comstock August 30, 2017
Outcome Health, which equips providers with screens displaying educational content, has added its first chief engineering officer to its ranks. Nandini Ramani, who most recently served as VP of Engineering at Twitter, will assume the post. "Healthcare is an industry close to my heart and Outcome Health's impact on society is tangible and meaningful," Ramani said in a statement. "In addition to...
By Jonah Comstock August 9, 2017
Brisbane, Australia-based digital health company ResApp has been talking up its Smartcough-C study — a multisite, double-blind study of the company’s smartphone-based respiratory analysis software — for a number of months. Conducted at Massachusetts General Hospital, Cleveland Clinic, and Texas Children’s Hospital, the trial was intended to support ResApp’s FDA submission for a number of...
By Heather Mack May 12, 2017
Virtual medical assistant company Sensely is collaborating with the Mayo Clinic to ascertain how to leverage patient engagement and chronic disease monitoring technology. The partnership will blend the Mayo Clinic’s triage algorithms and clinical expertise with Sensely’s patient engagement platform in hopes of assessing and predicting which resources can be best used at the right time to help...
By Heather Mack May 9, 2017
International medical organization Doctors Without Borders (Médecins sans Frontières, or MSF) is looking to evaluate the use of an app to diagnose and manage respiratory disease in rural, low-income settings. An unofficial collaboration is already in the works with Australian digital health company ResApp, whom MSF has indicated they are interested in working with in a clinical study. ResApp,...
By Jonah Comstock April 26, 2017
DarioHealth launches in the UK. Israel-based DarioHealth, makers of a smartphone-connected glucometer, announced the launch of a direct-to-consumer channel in the United Kingdom. It is already available D2C in the US and Australia, but was previously available in the UK only through pharmacies and diabetes educators. PlushCare launches telemedicine EMR. PlushCare, a D2C telemedicine service...
By Jonah Comstock November 16, 2016
ResApp has announced the final site and received the final IRB approval for its Smartcough-C trial. Texas Children's Hospital will join the previously announced Massachusetts General Hospital and Cleveland Clinic in a three-site trial of the Australian company's ResAppDx app, which essentially uses the smartphone microphone as a stethoscope to listen to a patient’s breathing. The double-blind...
By Jonah Comstock October 24, 2016
ResApp, an Australian company developing an app to diagnose respiratory conditions based on cough sounds, has secured the first of three IRB approvals for its upcoming Smartcough-C pediatric trial, which will take place at the Cleveland Clinic, Massachusetts General Hospital, and a third site yet to be announced. ResApp’s offering — an app called ResAppDx — essentially uses the smartphone...
By Heather Mack October 3, 2016
An app that essentially elevates coughing into a smartphone into a sophisticated diagnostic tool has performed well again in a clinical study. Australian digital health company ResApp, which makes a smartphone-based tool for diagnosing respiratory conditions, reported 91 to 100 percent accuracy with the app in a study of 243 patients spanning six different respiratory conditions. The results are...
By Jonah Comstock May 12, 2016
April was a big month for digital health funding, with 15 more deals coming through, totalling an impressive $220 million and bringing the total funding so far this year to $691 million. As we did in February with Oscar, we're excluding the largest deal, Bright Health's $80 million round, from the total because the company in question is a tech-saavy payer, but not a digital health company per se...
By Aditi Pai April 20, 2016
Australia-based ResApp, a public company, has raised $9.74 million ($12.5 million Australian dollars) for its product, a smartphone-based system for diagnosing respiratory conditions. The company sold 62.5 million new ordinary shares at $0.16 ($0.20 AU) per share. ResApp’s offering essentially uses the smartphone microphone as a stethoscope to listen to a patient’s breathing. But instead of...